CIMAvax EGF vaccine for stage IIIb/IV non-small cell lung carcinoma

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 12, 2012, Pages 1799-1801

  Cheng, Jian Y ^a,b   Kananathan, Ratnavelu ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b NCI Cancer Hospital   (Malaysia)

Author keywords

Cimavax; Epidermal growth factor (EGF); Lung; Non small cell lung cancer (NSCLC)

Indexed keywords

CANCER VACCINE; CARBOPLATIN; CHLORPHENIRAMINE; CIMAVAX RIGIMEN; CISPLATIN; EPIDERMAL GROWTH FACTOR; HYDROCORTISONE; PACLITAXEL; RECOMBINANT VACCINE; TRAMADOL; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADULT; ANAMNESIS; ANOREXIA; ARTICLE; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HEMOPTYSIS; HUMAN; INJECTION SITE PAIN; INJECTION SITE REACTION; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MULTIPLE CYCLE TREATMENT; PLEURA EFFUSION; TUMOR BIOPSY; TUMOR VOLUME; WEIGHT REDUCTION;

CIMAVAX; EPIDERMAL GROWTH FACTOR (EGF); LUNG; NON SMALL CELL LUNG CANCER (NSCLC);

CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; MIDDLE AGED; RADIOGRAPHY, THORACIC; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84872252849     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.21744     Document Type: Article

References (22)

1. Johnson DH. Chemotherapy for metastatic non-small-cell lung cancer - can that dog hunt? [Comment Editorial]. J Natl Cancer Inst 1993; 85:766-7; PMID:8387606; http://dx.doi.org/10.1093/jnci/85.10.766.
2. D'Addario G, Felip E; ESMO Guidelines Working Group. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. [Practice Guideline]. Ann Oncol 2008; 19(Suppl 2):ii39-40; PMID:18456762; http://dx.doi.org/10.1093/annonc/mdn081.
3. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-50; PMID:17167137; http://dx.doi.org/10.1056/ NEJMoa061884.
4. González G, Crombet T, Neninger E, Viada C, Lage A. Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: analysis of pooled data from three clinical trials. Hum Vaccin 2007; 3:8-13; PMID:17204867; http://dx.doi.org/10.4161/hv.3.1.3537.
5. Neninger Vinageras E, de la Torre A, Osorio Rodríguez M, Catalá Ferrer M, Bravo I, Mendoza del Pino M, et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol 2008; 26:1452-8; PMID:18349395; http://dx.doi.org/10.1200/JCO.2007.11.5980.
6. Lo HW, Hung MC. Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. Br J Cancer 2006; 94:184-8; PMID:16434982; http://dx.doi.org/10.1038/sj.bjc. 6602941.
7. Hirsch FR, Varella-Garcia M, Cappuzzo F. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene 2009; 28(Suppl 1):S32-7; PMID:19680294; http://dx.doi.org/10.1038/onc.2009.199.
8. Neninger E, Verdecia BG, Crombet T, Viada C, Pereda S, Leonard I, et al. Combining an EGF-based cancer vaccine with chemotherapy in advanced nonsmall cell lung cancer. [Clinical Trial]. J Immunother 2009; 32:92-9; PMID:19307998; http://dx.doi.org/10.1097/CJI.0b013e31818fe167.
9. Ramos TC, Vinageras EN, Ferrer MC, Verdecia BG, Rupalé IL, Pérez LM, et al. Treatment of NSCLC patients with an EGF-based cancer vaccine: report of a Phase I trial. Cancer Biol Ther 2006; 5:145-9; PMID:16357522; http://dx.doi.org/10.4161/cbt.5.2.2334.
10. García B, Neninger E, de la Torre A, Leonard I, Martínez R, Viada C, et al. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine. Clin Cancer Res 2008; 14:840-6; PMID:18245547; http://dx.doi.org/10.1158/1078-0432.CCR-07-1050.
11. Rodríguez PC, Rodríguez G, González G, Lage A. Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy. [Review]. MEDICC Rev 2010; 12:17-23; PMID:20387330.
12. Rodriguez PC, Gonzalez I, Gonzalez A, Avellanet J, Lopez A, Perez R, et al. Priming and boosting determinants on the antibody response to an Epidermal Growth Factor-based cancer vaccine. Vaccine 2008; 26:4647-54; PMID:18640164; http://dx.doi.org/10.1016/j.vaccine.2008.07.003.
13. Gonzalez G, Montero E, Leon K, Cohen IR, Lage A. Autoimmunization to epidermal growth factor, a component of the immunological homunculus. [Review]. Autoimmun Rev 2002; 1:89-95; PMID:12849064; http://dx.doi.org/10.1016/S1568- 9972(01)00015-5.
14. González G, Crombet T, Catalá M, Mirabal V, Hernández JC, González Y, et al. A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. Ann Oncol 1998; 9:431-5; PMID:9636835; http://dx.doi.org/10.1023/A:1008261031034.
15. Gonzalez G, Crombet T, Torres F, Catala M, Alfonso L, Osorio M, et al. Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy. Ann Oncol 2003; 14:461-6; PMID:12598354; http://dx.doi.org/10.1093/ annonc/mdg102.
16. González G, Lage A. Cancer vaccines for hormone/growth factor immune deprivation: a feasible approach for cancer treatment. Curr Cancer Drug Targets 2007; 7:229-41; PMID:17504120; http://dx.doi.org/10.2174/ 156800907780618310.
17. National Institutes of Health. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. National Cancer Institute; 2009 [cited 2012 28/7/12]; Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06- 14-QuickReference-5x7.pdf.
18. Brown SG, Mullins RJ, Gold MS. Anaphylaxis: diagnosis and management. [Review]. Med J Aust 2006; 185:283-9; PMID:16948628.
19. Graham BS, McElrath MJ, Keefer MC, Rybczyk K, Berger D, Weinhold KJ, et al.; AIDS Vaccine Evaluation Group. Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity. PLoS One 2010; 5:e11995; PMID:20706632; http://dx.doi.org/10.1371/journal.pone.0011995.
20. Pérez A, Dickinson F, Cinza Z, Ruíz A, Serrano T, Sosa J, et al. Safety and preliminary immunogenicity of the recombinant outer membrane protein P64k of Neisseria meningitidis in human volunteers. Biotechnol Appl Biochem 2001; 34:121-5; PMID:11592918; http://dx.doi.org/10.1042/BA20010029.
21. Toledo H, Baly A, Castro O, Resik S, Laferté J, Rolo F, et al. A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers. Vaccine 2001; 19:4328-36; PMID:11457560; http://dx.doi.org/10.1016/S0264-410X(01)00111-6.
22. Chiang CL, Kandalaft LE, Coukos G. Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines. Int Rev Immunol 2011; 30:150-82; PMID:21557641; http://dx.doi.org/10.3109/08830185.2011.572210.